Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy
Aims: To evaluate the results of chemoradiation with intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) for the treatment of anal canal cancer patients at three institutions that had advanced devices. Materials and Methods: A retrospective analysis was performed...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and therapeutics 2021-01, Vol.17 (1), p.51-55 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 55 |
|---|---|
| container_issue | 1 |
| container_start_page | 51 |
| container_title | Journal of cancer research and therapeutics |
| container_volume | 17 |
| creator | Yucel, Serap Kadioglu, Huseyin Gural, Zeynep Akgun, Zuleyha Saglam, Esra |
| description | Aims: To evaluate the results of chemoradiation with intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) for the treatment of anal canal cancer patients at three institutions that had advanced devices.
Materials and Methods: A retrospective analysis was performed for patients treated with 5-fluorouracil and mitomycin-based chemotherapy and IMRT or VMAT for anal cancer from 2011 to 2013. Complete response (CR) rates, colostomy-free survival (CFS), disease-free survival (DFS), overall survival (OS), and toxicities were investigated. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events, Version 3.0.
Results: Fifteen patients were included in the analysis. The majority of patients had T2 (53.3%) and N0 (40%) disease according to the staging system that was developed by the American Joint Committee on Cancer. CR was observed in 14 patients (93%), and the median follow-up was 26 months (13-42 months). The 3-year CFS, DFS, and OS were 86%, 86%, and 88%, respectively. Acute Grade 3 toxicities were observed as 6% of hematological, 26% of gastrointestinal, and 26% of dermatological.
Conclusion: Early results confirm that IMRT or VMAT for anal cancer treatment reduces acute toxicities while maintaining high control rates. |
| doi_str_mv | 10.4103/jcrt.JCRT_774_16 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2501850128</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A655948410</galeid><sourcerecordid>A655948410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c532s-ad273b0f728f6f9e9e53c4d4c47179604daadc5b3ba2aff2b596de22ddd0cc0b3</originalsourceid><addsrcrecordid>eNp1kl2LEzEUhoMobq3eeyUBb7yZmo_JfFyW4icLC7Jeh0xyZpvuTFKTzJb-Dv-wqd1KlUoIgZznfQ8neRF6TcmipIS_3-iQFl9X325lXZeSVk_QjLZtU5SUN0_RjLQ1L2jZsCv0IsYNIaJmrHmOrjivGaeczdDPmylpP0LEvsdblSy4FPHOpjVWTg1YK6ch4BRAJTDHwoMfphFSsLoYvZmG3xUVNE5rCGq7xz5g6xK4aNP-DAnKWH9ilDNYe6enEHJLrNcwnmov0bNeDRFePZ5z9P3jh9vV5-L65tOX1fK60IKzWCjDat6RvmZNX_UttCC4Lk2py5rWbUVKo5TRouOdYqrvWSfaygBjxhiiNen4HL07-m6D_zFBTHK0UcMwKAd-ipIJQpu8WZPRt_-gGz-F_EAHirNK1FycUXdqAGld71NQ-mAql5UQbdkcfm2OigvUHbg8_OAd9DZf_8UvLvB5GRitviggR4EOPsYAvdwGO6qwl5TIAyAPuZFnucmSN4_zTd0I5o_gFJQMLI_Azg8JQrwfph0Emdl753f_NZaCylPC-C_Tc9nK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2532657358</pqid></control><display><type>article</type><title>Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy</title><source>MEDLINE</source><source>Medknow Open Access Medical Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Yucel, Serap ; Kadioglu, Huseyin ; Gural, Zeynep ; Akgun, Zuleyha ; Saglam, Esra</creator><creatorcontrib>Yucel, Serap ; Kadioglu, Huseyin ; Gural, Zeynep ; Akgun, Zuleyha ; Saglam, Esra</creatorcontrib><description>Aims: To evaluate the results of chemoradiation with intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) for the treatment of anal canal cancer patients at three institutions that had advanced devices.
Materials and Methods: A retrospective analysis was performed for patients treated with 5-fluorouracil and mitomycin-based chemotherapy and IMRT or VMAT for anal cancer from 2011 to 2013. Complete response (CR) rates, colostomy-free survival (CFS), disease-free survival (DFS), overall survival (OS), and toxicities were investigated. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events, Version 3.0.
Results: Fifteen patients were included in the analysis. The majority of patients had T2 (53.3%) and N0 (40%) disease according to the staging system that was developed by the American Joint Committee on Cancer. CR was observed in 14 patients (93%), and the median follow-up was 26 months (13-42 months). The 3-year CFS, DFS, and OS were 86%, 86%, and 88%, respectively. Acute Grade 3 toxicities were observed as 6% of hematological, 26% of gastrointestinal, and 26% of dermatological.
Conclusion: Early results confirm that IMRT or VMAT for anal cancer treatment reduces acute toxicities while maintaining high control rates.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/jcrt.JCRT_774_16</identifier><identifier>PMID: 33723132</identifier><language>eng</language><publisher>India: Wolters Kluwer India Pvt. Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anal cancer ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Anus ; Anus Neoplasms - mortality ; Anus Neoplasms - pathology ; Anus Neoplasms - therapy ; Cancer ; Cancer therapies ; Care and treatment ; Chemoradiotherapy ; Chemotherapy ; Colorectal cancer ; Complications and side effects ; Female ; Fluorouracil - administration & dosage ; Humans ; Male ; Middle Aged ; Mitomycin - administration & dosage ; Neoplasm Staging ; Patient outcomes ; Radiotherapy ; Radiotherapy, Intensity-Modulated ; Retrospective Studies ; Survival Rate ; Terminology</subject><ispartof>Journal of cancer research and therapeutics, 2021-01, Vol.17 (1), p.51-55</ispartof><rights>COPYRIGHT 2021 Medknow Publications and Media Pvt. Ltd.</rights><rights>2021. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c532s-ad273b0f728f6f9e9e53c4d4c47179604daadc5b3ba2aff2b596de22ddd0cc0b3</citedby><cites>FETCH-LOGICAL-c532s-ad273b0f728f6f9e9e53c4d4c47179604daadc5b3ba2aff2b596de22ddd0cc0b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27456,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33723132$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yucel, Serap</creatorcontrib><creatorcontrib>Kadioglu, Huseyin</creatorcontrib><creatorcontrib>Gural, Zeynep</creatorcontrib><creatorcontrib>Akgun, Zuleyha</creatorcontrib><creatorcontrib>Saglam, Esra</creatorcontrib><title>Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy</title><title>Journal of cancer research and therapeutics</title><addtitle>J Cancer Res Ther</addtitle><description>Aims: To evaluate the results of chemoradiation with intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) for the treatment of anal canal cancer patients at three institutions that had advanced devices.
Materials and Methods: A retrospective analysis was performed for patients treated with 5-fluorouracil and mitomycin-based chemotherapy and IMRT or VMAT for anal cancer from 2011 to 2013. Complete response (CR) rates, colostomy-free survival (CFS), disease-free survival (DFS), overall survival (OS), and toxicities were investigated. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events, Version 3.0.
Results: Fifteen patients were included in the analysis. The majority of patients had T2 (53.3%) and N0 (40%) disease according to the staging system that was developed by the American Joint Committee on Cancer. CR was observed in 14 patients (93%), and the median follow-up was 26 months (13-42 months). The 3-year CFS, DFS, and OS were 86%, 86%, and 88%, respectively. Acute Grade 3 toxicities were observed as 6% of hematological, 26% of gastrointestinal, and 26% of dermatological.
Conclusion: Early results confirm that IMRT or VMAT for anal cancer treatment reduces acute toxicities while maintaining high control rates.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anal cancer</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Anus</subject><subject>Anus Neoplasms - mortality</subject><subject>Anus Neoplasms - pathology</subject><subject>Anus Neoplasms - therapy</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Complications and side effects</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mitomycin - administration & dosage</subject><subject>Neoplasm Staging</subject><subject>Patient outcomes</subject><subject>Radiotherapy</subject><subject>Radiotherapy, Intensity-Modulated</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Terminology</subject><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kl2LEzEUhoMobq3eeyUBb7yZmo_JfFyW4icLC7Jeh0xyZpvuTFKTzJb-Dv-wqd1KlUoIgZznfQ8neRF6TcmipIS_3-iQFl9X325lXZeSVk_QjLZtU5SUN0_RjLQ1L2jZsCv0IsYNIaJmrHmOrjivGaeczdDPmylpP0LEvsdblSy4FPHOpjVWTg1YK6ch4BRAJTDHwoMfphFSsLoYvZmG3xUVNE5rCGq7xz5g6xK4aNP-DAnKWH9ilDNYe6enEHJLrNcwnmov0bNeDRFePZ5z9P3jh9vV5-L65tOX1fK60IKzWCjDat6RvmZNX_UttCC4Lk2py5rWbUVKo5TRouOdYqrvWSfaygBjxhiiNen4HL07-m6D_zFBTHK0UcMwKAd-ipIJQpu8WZPRt_-gGz-F_EAHirNK1FycUXdqAGld71NQ-mAql5UQbdkcfm2OigvUHbg8_OAd9DZf_8UvLvB5GRitviggR4EOPsYAvdwGO6qwl5TIAyAPuZFnucmSN4_zTd0I5o_gFJQMLI_Azg8JQrwfph0Emdl753f_NZaCylPC-C_Tc9nK</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Yucel, Serap</creator><creator>Kadioglu, Huseyin</creator><creator>Gural, Zeynep</creator><creator>Akgun, Zuleyha</creator><creator>Saglam, Esra</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20210101</creationdate><title>Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy</title><author>Yucel, Serap ; Kadioglu, Huseyin ; Gural, Zeynep ; Akgun, Zuleyha ; Saglam, Esra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c532s-ad273b0f728f6f9e9e53c4d4c47179604daadc5b3ba2aff2b596de22ddd0cc0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anal cancer</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Anus</topic><topic>Anus Neoplasms - mortality</topic><topic>Anus Neoplasms - pathology</topic><topic>Anus Neoplasms - therapy</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Complications and side effects</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mitomycin - administration & dosage</topic><topic>Neoplasm Staging</topic><topic>Patient outcomes</topic><topic>Radiotherapy</topic><topic>Radiotherapy, Intensity-Modulated</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Terminology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yucel, Serap</creatorcontrib><creatorcontrib>Kadioglu, Huseyin</creatorcontrib><creatorcontrib>Gural, Zeynep</creatorcontrib><creatorcontrib>Akgun, Zuleyha</creatorcontrib><creatorcontrib>Saglam, Esra</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yucel, Serap</au><au>Kadioglu, Huseyin</au><au>Gural, Zeynep</au><au>Akgun, Zuleyha</au><au>Saglam, Esra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><addtitle>J Cancer Res Ther</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>17</volume><issue>1</issue><spage>51</spage><epage>55</epage><pages>51-55</pages><issn>0973-1482</issn><eissn>1998-4138</eissn><abstract>Aims: To evaluate the results of chemoradiation with intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) for the treatment of anal canal cancer patients at three institutions that had advanced devices.
Materials and Methods: A retrospective analysis was performed for patients treated with 5-fluorouracil and mitomycin-based chemotherapy and IMRT or VMAT for anal cancer from 2011 to 2013. Complete response (CR) rates, colostomy-free survival (CFS), disease-free survival (DFS), overall survival (OS), and toxicities were investigated. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events, Version 3.0.
Results: Fifteen patients were included in the analysis. The majority of patients had T2 (53.3%) and N0 (40%) disease according to the staging system that was developed by the American Joint Committee on Cancer. CR was observed in 14 patients (93%), and the median follow-up was 26 months (13-42 months). The 3-year CFS, DFS, and OS were 86%, 86%, and 88%, respectively. Acute Grade 3 toxicities were observed as 6% of hematological, 26% of gastrointestinal, and 26% of dermatological.
Conclusion: Early results confirm that IMRT or VMAT for anal cancer treatment reduces acute toxicities while maintaining high control rates.</abstract><cop>India</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>33723132</pmid><doi>10.4103/jcrt.JCRT_774_16</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-1482 |
| ispartof | Journal of cancer research and therapeutics, 2021-01, Vol.17 (1), p.51-55 |
| issn | 0973-1482 1998-4138 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2501850128 |
| source | MEDLINE; Medknow Open Access Medical Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over Anal cancer Antineoplastic Combined Chemotherapy Protocols - therapeutic use Anus Anus Neoplasms - mortality Anus Neoplasms - pathology Anus Neoplasms - therapy Cancer Cancer therapies Care and treatment Chemoradiotherapy Chemotherapy Colorectal cancer Complications and side effects Female Fluorouracil - administration & dosage Humans Male Middle Aged Mitomycin - administration & dosage Neoplasm Staging Patient outcomes Radiotherapy Radiotherapy, Intensity-Modulated Retrospective Studies Survival Rate Terminology |
| title | Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T15%3A13%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20of%20patients%20with%20anal%20cancer%20treated%20with%20volumetric-modulated%20arc%20therapy%20or%20intensity-modulated%20radiotherapy%20and%20concurrent%20chemotherapy&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=Yucel,%20Serap&rft.date=2021-01-01&rft.volume=17&rft.issue=1&rft.spage=51&rft.epage=55&rft.pages=51-55&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/jcrt.JCRT_774_16&rft_dat=%3Cgale_proqu%3EA655948410%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2532657358&rft_id=info:pmid/33723132&rft_galeid=A655948410&rfr_iscdi=true |